Dashboard
Manage Tickers

FUSNFusion Pharmaceuticals Inc.

Nasdaq fusionpharma.com


$ 21.44 $ 0.02 (0.09 %)    

Friday, 26-Apr-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 21.42
$ 21.39
$ 0.00 x 0
$ 0.00 x 0
$ 21.39 - $ 21.48
$ 2.31 - $ 21.55
351,216
na
1.41B
$ 0.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-20-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-16-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-10-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-25-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-11-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

top-4-health-care-stocks-that-may-plunge-this-month
Top 4 Health Care Stocks That May Plunge T...
04/26/2024 12:09:27

Core News & Articles
AstraZeneca, Through A Subsidiary, Will Ac...
04/25/2024 21:12:53

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjuca...

td-cowen-downgrades-fusion-pharmaceuticals-to-hold
TD Cowen Downgrades Fusion Pharmaceuticals...
04/16/2024 11:52:46

TD Cowen analyst Tara Bancroft downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold.

astrazeneca-hikes-annual-dividend-by-7-just-before-vote-on-its-ceos-pay-package-boost
AstraZeneca Hikes Annual Dividend By 7% Ju...
04/11/2024 13:04:00

AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CE...

fusion-pharmaceuticals-hightlights-presentation-of-interim-data-from-phase-2-tatcist-clinical-trial-evaluating-fpi-2265-at-the-aacr-annual-meeting-2024
Fusion Pharmaceuticals Hightlights Present...
04/09/2024 20:44:16

astrazeneca-ceo-highlights-decade-long-sales-goal-of-45b-along-with-investor-doubts-as-it-lags-in-weight-loss-race
AstraZeneca CEO Highlights Decade-Long Sal...
04/02/2024 18:54:01

AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. ...

rbc-capital-reiterates-sector-perform-on-fusion-pharmaceuticals-maintains-21-price-target
RBC Capital Reiterates Sector Perform on F...
03/21/2024 15:00:09

RBC Capital analyst Gregory Renza reiterates Fusion Pharmaceuticals (NASDAQ:FUSN) with a Sector Perform and maintains $21 pr...

wedbush-reiterates-neutral-on-fusion-pharmaceuticals-maintains-24-price-target
Wedbush Reiterates Neutral on Fusion Pharm...
03/21/2024 13:36:22

Wedbush analyst David Nierengarten reiterates Fusion Pharmaceuticals (NASDAQ:FUSN) with a Neutral and maintains $24 price ta...

recap-fusion-pharmaceuticals-q4-earnings
Recap: Fusion Pharmaceuticals Q4 Earnings
03/20/2024 21:30:22

fusion-pharmaceuticals-q4-2023-gaap-eps-039-misses-034-estimate
Fusion Pharmaceuticals Q4 2023 GAAP EPS $(...
03/20/2024 20:22:26

Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate...

raymond-james-downgrades-fusion-pharmaceuticals-to-market-perform
Raymond James Downgrades Fusion Pharmaceut...
03/20/2024 14:04:20

Raymond James analyst Rahul Sarugaser downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Strong Buy to Market Perform.

b-riley-securities-downgrades-fusion-pharmaceuticals-to-neutral-raises-price-target-to-23
B. Riley Securities Downgrades Fusion Phar...
03/20/2024 14:02:29

B. Riley Securities analyst Yuan Zhi downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Neutral and raises the pric...

truist-securities-downgrades-fusion-pharmaceuticals-to-hold-raises-price-target-to-21-report-released-on-19th-march-2024
Truist Securities Downgrades Fusion Pharma...
03/20/2024 12:46:41

Truist Securities analyst Nicole Germino downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold and raises the pri...

unveiling-11-analyst-insights-on-fusion-pharmaceuticals
Unveiling 11 Analyst Insights On Fusion Ph...
03/20/2024 12:01:19

rbc-capital-downgrades-fusion-pharmaceuticals-to-sector-perform-raises-price-target-to-21
RBC Capital Downgrades Fusion Pharmaceutic...
03/20/2024 11:26:31

RBC Capital analyst Gregory Renza downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Outperform to Sector Perform and rais...

jonestrading-downgrades-fusion-pharmaceuticals-to-hold
JonesTrading Downgrades Fusion Pharmaceuti...
03/20/2024 08:45:17

JonesTrading analyst Justin Walsh downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold.

nasdaq-turns-higher-caleres-posts-upbeat-q4-results
Nasdaq Turns Higher; Caleres Posts Upbeat ...
03/19/2024 19:02:35

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. The Dow...

why-peraso-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Peraso Shares Are Trading Lower By Ove...
03/19/2024 17:48:27

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
03/19/2024 17:31:02

dow-jumps-200-points-core--main-shares-gain-after-q4-results
Dow Jumps 200 Points; Core & Main Shares G...
03/19/2024 16:54:46

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION